Studies have shown that β-Elemene can enhance the sensitivity of EGFR-mutated non-small cell lung cancer to erlotinib by upregulating lncRNA H19 and inducing ferroptosis, providing a new approach to overcoming drug resistance in TNBC (Xu et al., 2023). Here, EGFR is linked to non-small cell lung carcinoma.